Clinical TrialMay 21, 2026, 08:07 AM
BioCardia CardiAMP CMI Trial Shows 179s Exercise Gain, 82% Angina Drop
AI Summary
BioCardia announced positive preliminary open-label cohort results from its CardiAMP Cell Therapy in Chronic Myocardial Ischemia (CMI) Trial at Euro PCR. The minimally invasive procedure was well tolerated with no major adverse cardiac events. Patients demonstrated significant improvements, including an average increase of 179 seconds in exercise tolerance and an 82% reduction in angina episodes, which persisted for up to two years.
Key Highlights
- BioCardia announced positive preliminary open-label cohort results from its CardiAMP CMI Trial.
- The CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events.
- Patients showed an average increase of 179 seconds in exercise tolerance, sustained for two years.
- Angina episodes were reduced by an average of 82% by six months after treatment.
- The therapy targets patients with severely symptomatic refractory angina who have exhausted other treatment options.
- CardiAMP Cell Therapy holds FDA Breakthrough Therapy designation for Ischemic Heart Failure.
Price Impact
More from BCDA